Keywords: otc, tavist, shows, rapid, growth, booming, market
OTC TAVIST SHOWS RAPID GROWTH
Article | 12 April 1993
A booming market for over-the-counter allergy remedies is expected to provide particular benefit for Sandoz' Tavist-1 (clemastine), which went OTC ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
